trending Market Intelligence /marketintelligence/en/news-insights/trending/oockcwmkanp19jdzoromiw2 content esgSubNav
In This List

Cellect Biotechnology appoints chief business officer

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cellect Biotechnology appoints chief business officer

Israel-based Cellect Biotechnology Ltd. named Andrew Sabatier as its chief business officer to head its U.S. center of operations.

Sabatier was most recently leading GE Cell Therapy's sales and market development for U.S. and Canada. Prior to joining GE, he was the sales vice president of Biosafe America Inc., a company acquired by General Electric Co.

Cellect Biotechnology is a biotechnology focused on developing technologies for selecting stem cells from any given tissue to improve a variety of related therapies.